Redeye comments on BioInvent’s first quarter in 2025. After our last update, BI-1808 obtained both Fast Track and Orphan Drug designations from the FDA. It is on track for a phase IIa readout by mid-year. Other programmes, including BI-1206, are also set for important readouts this year. Furthermore, the partnered asset mezagitamab moved into phase III, triggering a milestone payment.
LÄS MER
